Health Outcomes and Costs (HOC) in Lung Cancer (LC) (HOC-LC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02363101|
Recruitment Status : Unknown
Verified March 2015 by Carlos Gil Moreira Ferreira, Instituto Nacional de Cancer, Brazil.
Recruitment status was: Not yet recruiting
First Posted : February 13, 2015
Last Update Posted : March 4, 2015
|Condition or disease|
The costs will be assessed by micro-costing approach. All procedures involved in lung cancer at diagnosis, staging, treatment and best supportive care will be assessed.
The health-related quality of life will be assessed by EORTC-QLQ-C30, EQ-5D and EORTC-QLQ-LC13 in all different stages of lung cancer.
An utility measure will be considered. The preference values will be assessed via discrete choice experiment. Two scenarios will be designed and the lung cancer patients will be asked about the preferences.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Health Outcomes and Costs (HOC) in Brazilian Public Health Care System - The HOC Study in Lung Cancer|
|Study Start Date :||March 2015|
|Estimated Primary Completion Date :||March 2016|
|Estimated Study Completion Date :||December 2016|
- Direct costs [ Time Frame: one year ]Direct costs related to each procedure involved on lung cancer
- HRQoL [ Time Frame: up to 30 days after the procedure ]
- Preference values [ Time Frame: cross sectional ]Evaluate preference values in hypothetic scenarios
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02363101
|Contact: Luciene Schluckebieremail@example.com|
|Contact: Alessandra Marins||55 21 firstname.lastname@example.org|
|INCA - Instituto Nacional de Câncer||Not yet recruiting|
|Rio de Janeiro, Brazil|
|Contact: Luciene Schluckebier 55 21 32076660 email@example.com|
|Contact: Alessandra Marins 55 21 32076569 firstname.lastname@example.org|
|Principal Investigator:||Carlos Gil Ferreira||National Cancer Institute, France|
|Study Director:||Luciene Schluckebier||National Cancer Institute, France|
|Study Chair:||Marisa Santos||INC|
|Study Chair:||Bruna Carvalho||National Cancer Institute, France|
|Study Chair:||Pedro Masson||National Cancer Institute, France|
|Study Chair:||Andréa Monteiro||INC|
|Study Chair:||Bruna Medeiros||INC|
|Study Chair:||Kátia Senna||INC|
|Study Chair:||Márcia Gisele||INC|